Next Article in Journal / Special Issue
Folate Receptor Targeted Alpha-Therapy Using Terbium-149
Previous Article in Journal / Special Issue
Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy
 
 
Article

Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor

1
Center for Radiopharmaceutical Sciences of ETH-PSI-USZ, Department of Nuclear Medicine, University Hospital Zürich, CH-8091 Zürich, Switzerland
2
Center for Radiopharmaceutical Sciences of ETH-PSI-USZ, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zürich, Switzerland
3
Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, CH-9007 St. Gallen, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2014, 7(3), 339-352; https://doi.org/10.3390/ph7030339
Received: 20 January 2014 / Revised: 21 February 2014 / Accepted: 27 February 2014 / Published: 6 March 2014
(This article belongs to the Special Issue Radiopharmaceutical Chemistry between Imaging and Radioendotherapy)
Cannabinoid receptor subtype 2 (CB2) has been shown to be up-regulated in activated microglia and therefore plays an important role in neuroinflammatory and neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer’s disease. The CB2 receptor is therefore considered as a very promising target for therapeutic approaches as well as for imaging. A promising 2-oxoquinoline derivative designated KP23 was synthesized and radiolabeled and its potential as a ligand for PET imaging the CB2 receptor was evaluated. [11C]KP23 was obtained in 10%–25% radiochemical yield (decay corrected) and 99% radiochemical purity. It showed high stability in phosphate buffer, rat and mouse plasma. In vitro autoradiography of rat and mouse spleen slices, as spleen expresses a high physiological expression of CB2 receptors, demonstrated that [11C]KP23 exhibits specific binding towards CB2. High spleen uptake of [11C]KP23 was observed in dynamic in vivo PET studies with Wistar rats. In conclusion, [11C]KP23 showed promising in vitro and in vivo characteristics. Further evaluation with diseased animal model which has higher CB2 expression levels in the brain is warranted. View Full-Text
Keywords: cannabinoid receptor type 2 ligand; CB2 receptor; neurodegeneration; radiolabeling; autoradiography; small-animal PET cannabinoid receptor type 2 ligand; CB2 receptor; neurodegeneration; radiolabeling; autoradiography; small-animal PET
Show Figures

Figure 1

MDPI and ACS Style

Mu, L.; Slavik, R.; Müller, A.; Popaj, K.; Čermak, S.; Weber, M.; Schibli, R.; Krämer, S.D.; Ametamey, S.M. Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. Pharmaceuticals 2014, 7, 339-352. https://doi.org/10.3390/ph7030339

AMA Style

Mu L, Slavik R, Müller A, Popaj K, Čermak S, Weber M, Schibli R, Krämer SD, Ametamey SM. Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. Pharmaceuticals. 2014; 7(3):339-352. https://doi.org/10.3390/ph7030339

Chicago/Turabian Style

Mu, Linjing, Roger Slavik, Adrienne Müller, Kasim Popaj, Stjepko Čermak, Markus Weber, Roger Schibli, Stefanie D. Krämer, and Simon M. Ametamey. 2014. "Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor" Pharmaceuticals 7, no. 3: 339-352. https://doi.org/10.3390/ph7030339

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop